Oxford, UK, December 5 2019 - Oxford City Council’s East Area Planning Committee has approved the detailed plans for two office / laboratory buildings on The Oxford Science Park’s Plot 16 comprising 168,000 sq ft (15,600 sq m). The plans feature a central raised plaza and wider landscaping and accessibility enhancements.
• Mogrify platform recognized as having potential to transform future development of new medicines at prestigious awards ceremony
• Mogrify Chair receives Lifetime Achievement Award for contributions to biologics discovery and development
Favourable pharmacokinetic/pharmacodynamic profile compared to current best in class insulin treatment
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247. In the study, AT247 provided a favourable pharmacokinetic/pharmacodynamic profile compared with NovoRapid® and Fiasp®.
• Horizon’s HAP1 cell line to be integrated in the HPA Cell Atlas program
• Knockout cell models from Horizon chosen based on consistency and reproducibility demonstrated in validation studies
• Agreement will expand open access resource, supporting genetic research globally
Fieldfisher has solidified its reputation as leading legal advisers to the life sciences and healthcare industry, following the appointment of acclaimed life sciences lawyer Janita Good, to head up the practice from December.
As one of the few specialists in the UK for chemical and biochemical engineering design, the BioIndustry Association’s bioProcessUK conference is an extremely important annual meeting for us to meet our customers and share the latest industry trends in biologics manufacturing.
Aptus Clinical has been appointed full service clinical CRO partner by Artelo Biosciences Inc. (through their fully owned UK subsidiary, Trinity R&D Ltd). to deliver the upcoming Phase 1B/2A trial of their synthetic cannabinoid, ART27.13. This latest agreement builds on an earlier research and development partnership agreement, where Aptus successfully designed and supported the critical path pre-clinical experiments and completed key clinical strategy and planning activities for Artelo.
Magnitude Biosciences Limited, a spinout from Durham University offering contract research services in the field of ageing and age-related disease, today announces it has closed a second round of investment, making a total of £375,000 invested by the North East Innovation Fund, supported by the European Regional Development Fund and managed by Northstar Ventures, and Saker Capital.